Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Rhea-AI Summary

Unicycive Therapeutics, a clinical stage biotechnology company focused on kidney disease therapies, announced that CEO Shalabh Gupta will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The presentation can be accessed on the company's website under the Investors section starting January 10, 2022, at 7:00 a.m. ET. Unicycive is developing innovative treatments, including Renazorb, a phosphate binding agent for hyperphosphatemia, and UNI-494, a new chemical entity in late preclinical development for acute kidney injury.

LOS ALTOS, Calif., Jan. 10, 2022 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022.

The webcast will be accessible on the Unicycive website in the Investors section under Events and Presentations on Monday, January 10, 2022, at 7:00 a.m. ET.

About Unicycive

Unicycive Therapeutics, Inc. is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead product candidate, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com

Contacts:

ir@unicycive.com 
(650) 900-5470

View original content to download multimedia:https://www.prnewswire.com/news-releases/unicycive-therapeutics-to-present-at-the-hc-wainwright-bioconnect-virtual-conference-301456882.html

SOURCE Unicycive Therapeutics Inc.

FAQ

When will Unicycive Therapeutics present at the H.C. Wainwright BIOCONNECT Virtual Conference?

Unicycive Therapeutics will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10 to January 13, 2022.

Who is presenting for Unicycive Therapeutics at the conference?

Shalabh Gupta, M.D., the CEO of Unicycive Therapeutics, will be presenting at the conference.

What time does the Unicycive presentation begin on January 10, 2022?

The presentation by Unicycive Therapeutics will begin at 7:00 a.m. ET on January 10, 2022.

Where can I access the Unicycive Therapeutics presentation webcast?

The webcast of the Unicycive presentation will be available on their website under the Investors section.

What is the focus of Unicycive Therapeutics' product development?

Unicycive Therapeutics focuses on developing novel treatments for kidney diseases, including Renazorb for hyperphosphatemia and UNI-494 for acute kidney injury.